Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X (formerly Twitter) or LinkedIn.
How we work:
- PIONEER: We are courageous, resilient and rigorous in our mission to improve patients’ lives through our revolutionary degrader medicines.
- COLLABORATE: We value trust + transparency from everyone. Our goals are shared, our decisions data-driven and our camaraderie genuine.
- BELONG: We recognize our differences, inviting curiosity and inclusivity, so that our people are valued, seen, and heard.
How you’ll make an impact:
- Working closely with program teams towards addressing key biology and chemistry questions
- Develop and optimize sample preparation and mass spectrometry methods for deep quantitative analysis of cell and tissue total proteomes as well as post-translational modifications.
- Perform maintenance, quality control and troubleshooting of instruments, including HPLCs and mass spectrometers
- Establish robust nLC-MS-based data acquisition and analysis workflows
- Provide documentation, analysis, interpretation and presentation of experimental data in a clear and concise manner
- Present scientific results and strategic recommendations to internal project teams, senior leadership, and external collaborators in a clear, concise, and influential manner.
- Stay up to date on proteomics methods and technologies
- Proactively recognize and solve technical and scientific issues to ensure high quality proteomics data is generated for the progression of drug discovery projects.
Skills and experience you’ll bring:
- PhD in Biochemistry, Biology, Chemical Biology, or a related discipline, with 3+ years of quantitative mass spectrometry-based proteomics experience, or 7+ years of industry experience in proteomics.
- Extensive hands-on experience in proteomics is required including:
- Demonstrated ability to independently troubleshoot, analyze, and interpret proteomics data with attention to detail, to recommend and execute next steps.
- High level of proficiency in a variety of quantitative proteomics techniques including DIA, label-free quantification and peptide fragmentation methods.
- Maintaining and troubleshooting HPLCs and mass spectrometers.
- Developing methods and performing nano LC-MS/MS experiments using Orbitrap Astral or Orbitrap Exploris 480 mass spectrometers.
- Experience in computational analysis and downstream statistical analysis software packages, such as DIANN, Perseus, R or Python, to address key program questions.
- Ability to work in an agile, fast-paced, team-oriented environment.
- Lead from the lab for activities include hit validation, lead optimization, target validation, and small molecule mechanism of action studies
- Experience with PTM analysis (phosphorylation and ubiquitination), protein interaction analysis, and targeted proteomics are a plus.
- Experience in low abundance protein isolation from complex biological samples including cells, tissue and biofluids and affinity enrichment to selectively enrich sub-proteomes and experience with automation and liquid handling systems are a plus.
- Experience in mapping protein-protein interactions by mass spectrometry with pulldown approaches, proximity labeling and XL-MS are a plus
- Tissue culture experience with suspension and adherent cell lines is a plus
Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment. All applicants will receive consideration for employment without regard to race, color, religion, creed, gender, national origin, age, disability, veteran status, pregnancy, sex, marital status, gender expression or identity, genetic information, sexual orientation, citizenship, or any other legally protected class.
Compensation
- Kymera offers a competitive compensation package that recognizes both results and capabilities through market-based, performance-driven pay.
- The anticipated base salary range for this role is $90,000 – $200,000, with eligibility for annual bonus, equity participation, and comprehensive benefits.
- Actual salary is based on a holistic evaluation of the specific role/level as well as each candidate’s depth of experience and the capabilities they bring to the position.
Skills Required
- PhD in Biochemistry, Biology, Chemical Biology, or related discipline
- 3+ years of quantitative mass spectrometry-based proteomics experience or 7+ years of industry experience
- Extensive hands-on experience in proteomics
- Proficiency in quantitative proteomics techniques including DIA
- Experience in maintaining and troubleshooting HPLCs and mass spectrometers
- Experience in computational analysis using R or Python
Kymera Therapeutics Compensation & Benefits Highlights
The following summarizes recurring compensation and benefits themes identified from responses generated by popular LLMs to common candidate questions about Kymera Therapeutics and has not been reviewed or approved by Kymera Therapeutics.
-
Fair & Transparent Compensation — Pay is considered market‑competitive for core scientific and leadership roles, with clearly posted ranges visible for U.S. openings. Feedback suggests strong base pay aligns with comments about high salary and good pay.
-
Equity Value & Accessibility — Employees are eligible to participate in broad‑based equity programs, including an equity incentive plan and an ESPP. Feedback suggests this ownership opportunity can meaningfully augment total compensation in a growth‑focused setting.
-
Leave & Time Off Breadth — Company‑wide office shutdowns, standard PTO, and summer schedules are promoted to help people unplug. Feedback suggests these practices contribute to a well‑rounded time‑off offering.
Kymera Therapeutics Insights
What We Do
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years



.jpg)




